Zimmer Biomet Earns 510(k) for G7 TM Acetabular System .
The article reports that Zimmer Biomet has received U.S. Food & Drug Administration (FDA) 510(k) clearance to market its G7 TM Acetabular System, a next-generation hip replacement implant designed for challenging primary and revision total hip arthroplasty cases. The system builds on the established G7 platform by combining Trabecular Metal® porous technology with a strategically placed anatomic screw-hole pattern and Rim Fix™ screws to support stable fixation in compromised bone and promote biological integration. It is compatible with multiple G7 liners, including dual mobility and constrained options, and is expected to begin U.S. commercialization with full launch anticipated by the end of the first quarter of 2026.
Read the full News article from BoneZone
Read Article
DISCLAIMER
This content found on this page is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. If you require medical treatment, always seek the advice of your physician or go to your nearest emergency department. The opinions, beliefs, and viewpoints expressed by the individuals on the content found on this page do not reflect the opinions, beliefs, and viewpoints of OrthoEvidence.
